ADGLYSS

Class [005]
Pharmaceutical preparations namely pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders namely osteoporosis, osteoarthritis, fracture healing, bone frailty due to extended ventilator use, hip replacement surgery and knee replacement surgery, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, arthritis, bursitis, tendonitis, osteonecrosis and Paget's disease, cancer, cardiovascular diseases, central nervous system diseases and disorders namely, anxiety disorders, depression, bipolar depression, bipolar disorder, treatment resistant depression, schizophrenia and cognitive impairment associated with schizophrenia, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders namely psoriasis, skin cancer and eczema, diabetes, dyslipidemia, endocrine diseases and disorders, namely Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders namely inflammatory bowel diseases, inflammatory connective tissue diseases and rheumatoid arthritis, kidney diseases and disorders, liver diseases and disorders, lupus, mental diseases and disorders, namely mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, and cerebral palsy, metabolic diseases and disorders namely metabolic syndrome, migraines, neurodegenerative diseases and disorders namely Huntington's disease, Alzheimer's disease, and dementia, neurological disorders namely Alzheimer's disease, mild cognitive impairment, Parkinson's disease and multiple sclerosis, obesity, osteoarthritis, pain relief, Parkinson's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; vascular diseases; Diagnostic agents, preparations and substances for medical diagnostic purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases.